IGF-1 LR3
Research Use Only | Not for Human Consumption
A modified analog of human Insulin-like Growth Factor-1 with a 13-amino-acid N-terminal extension and an arginine substitution at position 3
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a recombinant analog of human IGF-1. The 'Long' refers to a 13-amino-acid extension at the N-terminus, and 'R3' indicates an arginine substitution at position 3, a modification that reduces affinity for IGF-binding proteins in preclinical research models. Supplied in lyophilized form.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 946870-92-4 | C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉ | 9117.6 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A modified IGF-1 analog with a 13-amino-acid N-terminal extension and Arg-3 substitution
What is IGF-1 LR3?
IGF-1 LR3 emerged from research efforts in the late 1980s and early 1990s to create modified versions of insulin-like growth factor with altered binding profiles. Scientists at GroPep in Adelaide, Australia, were among the first to develop this modified peptide, characterizing it in the context of native IGF-1's rapid sequestration by circulating binding proteins.
The key structural change was twofold: adding 13 extra amino acids to the N-terminus of the peptide sequence and substituting arginine for glutamic acid at position 3. These modifications reduced affinity for IGF-binding proteins (IGFBPs) in preclinical assays, yielding a research-grade analog with a longer apparent half-life in in-vitro and animal models than native IGF-1.
Since its development, IGF-1 LR3 has appeared in peer-reviewed preclinical publications examining IGF-1 receptor signaling in cell culture and animal models. Its reduced IGFBP affinity makes it a common tool compound for investigating IGF-1R-mediated pathways in research settings. This product is intended for research use only.
What is IGF-1 LR3 studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
Organ-Mass & Anabolic Signaling Research (Preclinical)
In preclinical guinea pig infusion models, LR3 IGF-I has been examined for associations with organ mass changes across adrenals, gut, kidneys, and spleen.
ERK & PI3K Signaling Research (Preclinical)
In fetal sheep preclinical studies, LR3 IGF-1 has been investigated for its interactions with cardiomyocyte ERK and PI3K signaling cascades.
Phospho-Akt & SOCS3 Expression Research (Preclinical)
In murine preclinical models, LR3-IGF-I has been examined for its associations with mammary phospho-Akt signaling and SOCS3 gene expression profiles.
Amyloid-Pathway CNS Research (Preclinical)
In preclinical Alzheimer's disease mouse models, intranasal LR3-IGF-1 has been investigated for associations with amyloid plaque remodeling markers.
How should IGF-1 LR3 be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All IGF-1 LR3 batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with IGF-1 LR3
Add all 3 items to your cart
$260
Clinical References
- Francis GL, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992;8(3):213-223. PubMed: 1378742
- Tomas FM, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochemical Journal. 1992;282(Pt 1):91-97. PubMed: 1371669
- Ballard FJ, et al. Does IGF-I ever act through the insulin receptor? Cytokine & Growth Factor Reviews. 2007;18(1-2):7-12.
